These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 29407964)
21. Computational Screening and Design for Compounds that Disrupt Protein-protein Interactions. Johnson DK; Karanicolas J Curr Top Med Chem; 2017; 17(23):2703-2714. PubMed ID: 28482793 [TBL] [Abstract][Full Text] [Related]
22. Therapeutic Developments Targeting Toll-like Receptor-4-Mediated Neuroinflammation. Li J; Csakai A; Jin J; Zhang F; Yin H ChemMedChem; 2016 Jan; 11(2):154-65. PubMed ID: 26136385 [TBL] [Abstract][Full Text] [Related]
23. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Forli S; Huey R; Pique ME; Sanner MF; Goodsell DS; Olson AJ Nat Protoc; 2016 May; 11(5):905-19. PubMed ID: 27077332 [TBL] [Abstract][Full Text] [Related]
24. Discovery of new erbB4 inhibitors: Repositioning an orphan chemical library by inverse virtual screening. Giordano A; Forte G; Massimo L; Riccio R; Bifulco G; Di Micco S Eur J Med Chem; 2018 May; 152():253-263. PubMed ID: 29730188 [TBL] [Abstract][Full Text] [Related]
25. Discovery of novel pneumococcal surface antigen A (PsaA) inhibitors using a fragment-based drug design approach. Bajaj M; Mamidyala SK; Zuegg J; Begg SL; Ween MP; Luo Z; Huang JX; McEwan AG; Kobe B; Paton JC; McDevitt CA; Cooper MA ACS Chem Biol; 2015 Jun; 10(6):1511-20. PubMed ID: 25786639 [TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of small molecules as potent glucosidase inhibitors. Hati S; Madurkar SM; Bathula C; Thulluri C; Agarwal R; Siddiqui FA; Dangi P; Adepally U; Singh A; Singh S; Sen S Eur J Med Chem; 2015 Jul; 100():188-96. PubMed ID: 26087029 [TBL] [Abstract][Full Text] [Related]
27. Virtual medicinal chemistry: in silico pre-docking functional group transformation for discovery of novel inhibitors of botulinum toxin serotype A light chain. O'Malley S; Sareth S; Jiao GS; Kim S; Thai A; Cregar-Hernandez L; McKasson L; Margosiak SA; Johnson AT Bioorg Med Chem Lett; 2013 May; 23(9):2505-11. PubMed ID: 23545109 [TBL] [Abstract][Full Text] [Related]
28. Discovery of potent inhibitors of receptor protein tyrosine phosphatase sigma through the structure-based virtual screening. Park H; Chien PN; Ryu SE Bioorg Med Chem Lett; 2012 Oct; 22(20):6333-7. PubMed ID: 22989533 [TBL] [Abstract][Full Text] [Related]
29. TLR4/MD2 specific peptides stalled in vivo LPS-induced immune exacerbation. Park S; Shin HJ; Shah M; Cho HY; Anwar MA; Achek A; Kwon HK; Lee B; Yoo TH; Choi S Biomaterials; 2017 May; 126():49-60. PubMed ID: 28254693 [TBL] [Abstract][Full Text] [Related]
30. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist. Cho NC; Seo SH; Kim D; Shin JS; Ju J; Seong J; Seo SH; Lee I; Lee KT; Kim YK; No KT; Pae AN J Comput Aided Mol Des; 2016 Aug; 30(8):625-37. PubMed ID: 27600555 [TBL] [Abstract][Full Text] [Related]
31. Rational design of novel irreversible inhibitors for human arginase. Guo X; Chen Y; Seto CT Bioorg Med Chem; 2018 Aug; 26(14):3939-3946. PubMed ID: 29914772 [TBL] [Abstract][Full Text] [Related]
32. Structural insights on identification of potential lead compounds targeting WbpP in Vibrio vulnificus through structure-based approaches. Sasikala D; Jeyakanthan J; Srinivasan P J Recept Signal Transduct Res; 2016 Oct; 36(5):515-30. PubMed ID: 26795501 [TBL] [Abstract][Full Text] [Related]
33. Discovery of novel nonpeptide small-molecule NRP1 antagonists: Virtual screening, molecular simulation and structural modification. Peng K; Li Y; Bai Y; Jiang T; Sun H; Zhu Q; Xu Y Bioorg Med Chem; 2020 Jan; 28(1):115183. PubMed ID: 31744780 [TBL] [Abstract][Full Text] [Related]
34. CD14 dependence of TLR4 endocytosis and TRIF signaling displays ligand specificity and is dissociable in endotoxin tolerance. Rajaiah R; Perkins DJ; Ireland DD; Vogel SN Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8391-6. PubMed ID: 26106158 [TBL] [Abstract][Full Text] [Related]
35. Ligand-selective small molecule modulators of the constitutively active vGPCR US28. Amărandi RM; Lückmann M; Melynis M; Jakobsen MH; Fallah Z; Spiess K; Hjortø GM; Pui A; Frimurer TM; Rosenkilde MM Eur J Med Chem; 2018 Jul; 155():244-254. PubMed ID: 29886326 [TBL] [Abstract][Full Text] [Related]
36. Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow. Kouskoumvekaki I; Petersen RK; Fratev F; Taboureau O; Nielsen TE; Oprea TI; Sonne SB; Flindt EN; Jónsdóttir SÓ; Kristiansen K J Chem Inf Model; 2013 Apr; 53(4):923-37. PubMed ID: 23432662 [TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of small molecule inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening. Zhang M; Zhu W; Ding N; Zhang W; Li Y Bioorg Med Chem Lett; 2013 Apr; 23(7):2225-9. PubMed ID: 23434226 [TBL] [Abstract][Full Text] [Related]
38. Structure-based discovery of novel US28 small molecule ligands with different modes of action. Lückmann M; Amarandi RM; Papargyri N; Jakobsen MH; Christiansen E; Jensen LJ; Pui A; Schwartz TW; Rosenkilde MM; Frimurer TM Chem Biol Drug Des; 2017 Mar; 89(3):289-296. PubMed ID: 27569905 [TBL] [Abstract][Full Text] [Related]
39. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors. Sakkiah S; Thangapandian S; John S; Lee KW Eur J Med Chem; 2011 Jul; 46(7):2937-47. PubMed ID: 21531051 [TBL] [Abstract][Full Text] [Related]
40. Chemical-Space-Based de Novo Design Method To Generate Drug-Like Molecules. Takeda S; Kaneko H; Funatsu K J Chem Inf Model; 2016 Oct; 56(10):1885-1893. PubMed ID: 27632418 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]